Vinge advises Medicover AB (publ) (“Medicover”) and its main shareholder Celox Holding AB (“Celox”), which is wholly owned by the charitable foundation the Jonas and Christina af Jochnick Foundation, in relation to Medicover’s listing on Nasdaq Stockholm.
Trading in Medicover’s B share on Nasdaq Stockholm commences today, 23 May 2017. The price in the offering was set at SEK 56 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 7.5 billion. Assuming full exercise of the over-allotment option in the offering, the value of the offering will amount to approximately SEK 2.3 billion.
Medicover is a leading international healthcare and diagnostic services provider in Poland, Germany, Romania, Ukraine and certain other markets, primarily in Central and Eastern Europe (“CEE”). Additionally, Medicover is in the process of entering the fast-growing Indian healthcare market in order to expand its geographical footprint and further leverage its emerging markets capabilities. Medicover offers a broad range of healthcare services and a significant hub-and-spoke diagnostic laboratory network, supported by extensively developed proprietary software and information systems infrastructure. Medicover operates through two divisions: Healthcare Services and Diagnostic Services.
Vinge’s team primarily consists of Dain Hård Nevonen, Erik Sjöman, Ludvig Frithiof, Sofie Bjärtun, Louise Nordkvist and Astrid Karlsson.